158 related articles for article (PubMed ID: 36120784)
1. Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.
Baldeiras I; Silva-Spínola A; Lima M; Leitão MJ; Durães J; Vieira D; Tábuas-Pereira M; Cruz VT; Rocha R; Alves L; Machado Á; Milheiro M; Santiago B; Santana I
J Alzheimers Dis; 2022; 90(1):419-432. PubMed ID: 36120784
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
[TBL] [Abstract][Full Text] [Related]
3. Exploring the ATN classification system using brain morphology.
Heinzinger N; Maass A; Berron D; Yakupov R; Peters O; Fiebach J; Villringer K; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Bartels C; Jessen F; Maier F; Glanz W; Buerger K; Janowitz D; Perneczky R; Rauchmann BS; Teipel S; Killimann I; Göerß D; Laske C; Munk MH; Spottke A; Roy N; Heneka MT; Brosseron F; Dobisch L; Ewers M; Dechent P; Haynes JD; Scheffler K; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Düzel E; Ziegler G;
Alzheimers Res Ther; 2023 Mar; 15(1):50. PubMed ID: 36915139
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
[TBL] [Abstract][Full Text] [Related]
5. Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO.
Ismail Z; Leon R; Creese B; Ballard C; Robert P; Smith EE
Mol Neurodegener; 2023 Jul; 18(1):50. PubMed ID: 37516848
[TBL] [Abstract][Full Text] [Related]
6. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
7. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
9. A + T ± status across MCI and dementia due to AD: a clinic-based, retrospective study.
Verde F; Aiello EN; Milone I; Giacopuzzi Grigoli E; Dubini A; Ratti A; Poletti B; Ticozzi N; Silani V
Neurol Sci; 2022 Nov; 43(11):6547-6550. PubMed ID: 35972620
[TBL] [Abstract][Full Text] [Related]
10. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.
Xiong X; He H; Ye Q; Qian S; Zhou S; Feng F; Fang EF; Xie C
CNS Neurosci Ther; 2024 Feb; 30(2):e14357. PubMed ID: 37438991
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal change in ATN biomarkers in cognitively normal individuals.
Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
[TBL] [Abstract][Full Text] [Related]
13. Using the ATN system as a guide for the neuropsychological assessment of Alzheimer's disease.
Florean I; Penolazzi B; Menichelli A; Pastore M; Cattaruzza T; Mazzon G; Manganotti P
J Clin Exp Neuropsychol; 2021 Nov; 43(9):926-943. PubMed ID: 35166171
[TBL] [Abstract][Full Text] [Related]
14. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW
Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893
[TBL] [Abstract][Full Text] [Related]
15. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
Rosenberg A; Öhlund-Wistbacka U; Hall A; Bonnard A; Hagman G; Rydén M; Thunborg C; Wiggenraad F; Sandebring-Matton A; Solomon A; Kivipelto M
Neurology; 2022 Nov; 99(19):e2102-e2113. PubMed ID: 36130840
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
17. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders.
Régy M; Dugravot A; Sabia S; Bouaziz-Amar E; Paquet C; Hanseeuw B; Singh-Manoux A; Dumurgier J
Alzheimers Res Ther; 2023 Apr; 15(1):77. PubMed ID: 37038213
[TBL] [Abstract][Full Text] [Related]
18. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
[TBL] [Abstract][Full Text] [Related]
19. Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum.
Seo EH; Lim HJ; Yoon HJ; Choi KY; Lee JJ; Park JY; Choi SH; Kim H; Kim BC; Lee KH
Alzheimers Res Ther; 2021 Oct; 13(1):167. PubMed ID: 34627371
[TBL] [Abstract][Full Text] [Related]
20. The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up.
Grøntvedt GR; Lauridsen C; Berge G; White LR; Salvesen Ø; Bråthen G; Sando SB
J Alzheimers Dis; 2020; 74(3):829-837. PubMed ID: 32116257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
